申请人:Lynch R. Kevin
公开号:US20070088002A1
公开(公告)日:2007-04-19
The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R
11
is C
5
-C
18
alkyl or C
5
-C
18
alkenyl; Q is selected from the group consisting of C
3
-C
6
optionally substituted cycloalkyl, C
3
-C
6
optionally substituted heterocyclic, C
3
-C
6
optionally substituted aryl C
3
-C
6
optionally substituted heteroaryl and; R
2
is selected from the group consisting of H, C
1
-C
4
alkyl, (C
1
-C
4
alkyl)OH and (C
1
-C
4
alkyl)NH
2
; R
23
is H or C
1
-C
4
alkyl, and R
15
is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.
本发明涉及具有S1P受体调节剂活性的S1P类似物,并使用这些化合物治疗与不适当S1P受体活性相关的疾病。这些化合物具有一般结构(I),其中R11为C5-C18烷基或C5-C18烯基;Q选自C3-C6可选取代的环烷基、C3-C6可选取代的杂环、C3-C6可选取代的芳基、C3-C6可选取代的杂芳基;R2选自H、C1-C4烷基、(C1-C4烷基)OH和(C1-C4烷基)NH2;R23为H或C1-C4烷基,R15为磷酸酯或磷酸酯酯或其药学上可接受的盐或互变异构体。